GHK-Cu peptide.

GHK-Cu is a copper-binding tripeptide

GHK-Cu combines three amino acids—glycine, histidine and lysine—with copper. GHK names the peptide; Cu names its bound copper ion. The supplied compound is a 1:1 complex, also called copper tripeptide-1. A 100 mg label describes the whole complex, not 100 mg of elemental copper. [1]

GHK was isolated from human plasma. That origin explains the description “naturally occurring peptide”; the material in a research vial is manufactured. A molecule being present in the body does not identify a useful amount to add. [2]

The main consumer questions concern skin texture, fine lines, hair and tissue repair. These are separate outcomes. A smoother skin surface is a cosmetic result. A closing wound is a medical result. A thicker eyebrow hair is a different measurement again. The formulation and the measured change need to match the benefit being claimed.

GHK-Cu benefits for skin and hair

Topical results belong to the tested topical product. A cream or serum places a formulated ingredient on a skin surface. The supplied pen and nasal spray deliver it differently. Their concentration, absorption and tissue exposure cannot be read from a cosmetic trial.

The GHK-Cu benefits article covers skin firmness, scars, wounds, eyebrow and scalp-hair claims separately. It also explains why AHK-Cu hair-follicle experiments are often incorrectly presented as GHK-Cu clinical results.

Collagen, skin support and concentration

GHK-Cu research concerns how cells build and remodel the material around them. Collagen supplies structural support. Other components help organise that support and hold water. Together, these materials form the extracellular matrix: the surrounding framework of a tissue.

In cultured human fibroblasts, GHK-Cu increased certain glycosaminoglycans, including dermatan sulphate and heparan sulphate. It did not increase hyaluronic-acid synthesis in that experiment. The response rose at lower concentrations and returned toward baseline at higher concentrations. [6]

Those are three different measurements. A bigger vial does not prove a larger biological effect. Diluting a vial changes the liquid volume needed for a target amount; it does not establish a better treatment. Cell-culture concentrations also cannot be converted directly into a daily injected dose for a person.

Daily dosage and syringe units

2 mg, or 2,000 mcg, once daily by subcutaneous injection appears in a documented 30-day use account. It is an individual example, not a dose-finding trial or an established starting dose. [7]

The calculator starts with a 100 mg vial at 2 mL final volume. That gives 50 mg/mL. At this concentration, one U-100 unit contains 500 mcg, and four units contain 2 mg. At 3 mL final volume, the same 2 mg needs six units. The target amount stays the same; its liquid volume changes.

Enter your own target amount first in the GHK-Cu dosage calculator. The live syringe graphic moves with the calculation. The tool converts mass to volume; it does not select a treatment amount or validate a preparation method.

“2 mg daily” means 2 mg across the whole day. Two separate 2 mg administrations total 4 mg. GHK-Cu already present in GLOW or KLOW also counts toward the combined amount.

Cycle length, frequency and supply

An 11-week individual account used 1.5–2.5 mg on five days each week. That staged schedule differs from the 30-day daily example. Neither establishes an ideal course or a proven break between courses. [8]

For a simple quantity calculation, 2 mg across 30 active days totals 60 mg. Two milligrams across five days weekly totals 10 mg per week; across seven days it totals 14 mg. A schedule needs both the amount and the number of active days.

A 100 mg vial holds fifty theoretical 2 mg portions. The 150 mg pen holds seventy-five. Those numbers exclude losses and discard limits. Enough material for a long course does not mean a prepared container remains suitable for that long.

The course-quantity table calculates whole vials and pens. Timing, food questions, reconstitution and general subcutaneous sites appear earlier on the same page.

100 mg vial, nasal spray and 150 mg pen

The pen contains 50% more labelled GHK-Cu than the 100 mg vial. It arrives as 3 mL at 50 mg/mL. The nasal spray is listed as 100 mg, but its exact fill and amount per pump are unconfirmed. [1]

Research-labelled products. Drawings show the formats; they are not product photographs.

The vial needs preparation. Its final liquid concentration depends on the mixed volume. The documented powder storage is −20°C, dry and dark; the documented prepared-vial storage is 2–8°C. No universal post-mixing expiry is supplied.

The pen has a fixed concentration. On the owner-supplied 300-marked-unit scale across 3 mL, each marked unit represents 0.01 mL and 500 mcg. A mechanical click has not been verified as one marked unit. The cartridge arrives dissolved, so no water is added.

The spray needs a verified pump measurement. A bottle's total milligrams cannot determine micrograms per press. That calculation requires both concentration and liquid delivered by one press. Generic bottle-size assumptions would create a false number.

The pen and spray specify 2–8°C storage, protection from light and no freezing. The three-format comparison includes preparation, storage, amount per unit and the exact scope of the attached report. [1]

Skin and hair results over time

Better skin feel and measured wrinkle reduction are different outcomes. Likewise, fuller-looking hair can reflect texture or styling as well as the number of hairs. These accounts do not establish an injection response rate or a deadline for visible regrowth.

See the before-and-after results for the study measurements, time points and exact formulations.

GHK-Cu in GLOW and KLOW

Both blends already contain the copper peptide. The 70 mg GLOW vial includes 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. The 80 mg KLOW vial adds 10 mg KPV to those same quantities. [9] [10]

Add 2 mg standalone GHK-Cu to either blend amount above and the combined GHK-Cu becomes 4.5 mg. The additional material does not replace the GHK-Cu already present. Product names can hide that overlap when only total blend milligrams are compared.

Standalone GHK-Cu allows its amount to change without changing other peptide ingredients. A fixed blend changes all ingredients together. Neither arrangement establishes that combining products improves skin or hair outcomes. The GLOW peptide and KLOW peptide guides give their own component calculators and product specifications.

Side effects and copper exposure

Injection discomfort does not measure how well the peptide is working. Persistent or worsening reactions need assessment before further exposure. New symptoms also cannot identify copper excess without an appropriate medical assessment.

The side-effects article covers local reactions, copper-handling disorders, ingredient overlap and the difference between whole-complex mass and elemental copper. Dietary copper limits cannot be treated as injection limits.

Redacted COA: lot PL-2609-036

The supplied powder-lot certificate records 99.62% RP-HPLC area purity. It also records LC-MS identity at 402.1 Da, endotoxin at 0.04 EU/mg and no growth in a 14-day sterility test. Two powder vials were sampled from a 250-unit lot. [11]

These are distinct tests. HPLC area purity describes the relative chromatographic peak area. It is not a quantitative check that a vial contains exactly 100 mg. The report contains no separate elemental-copper assay, and its powder-lot results do not establish finished-pen or spray content, sterility or batch linkage.

The redacted two-page COA is available beside the product comparison, with its issue date, test results and sample scope intact. Match the received lot to the report before treating the certificate as documentation for that container.